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Abstract
Background: Deletions of 6q15–16.1 are recurrently found in pediatric T-cell acute lymphoblastic leukemia (T-ALL).
This chromosomal region includes the mitogen-activated protein kinase kinase kinase 7 (MAP3K7) gene which has a
crucial role in innate immune signaling and was observed to be functionally and prognostically relevant in different
cancer entities. Therefore, we correlated the presence of MAP3K7 deletions with clinical parameters in a cohort of 327
pediatric T-ALL patients and investigated the function of MAP3K7 in the T-ALL cell lines CCRF-CEM, Jurkat and MOLT-4.
Methods: MAP3K7 deletions were detected by multiplex ligation-dependent probe amplification (MLPA). T-ALL cell
lines were transduced with adeno-associated virus (AAV) vectors expressing anti-MAP3K7 shRNA or a non-silencing
shRNA together with a GFP reporter. Transduction efficiency was measured by flow cytometry and depletion efficiency
by RT-PCR and Western blots. Induction of apoptosis was measured by flow cytometry after staining with PE-
conjugated Annexin V. In order to assess the contribution of NF-κB signaling to the effects of MAP3K7 depletion, cells
were treated with TNF-α and cell lysates analyzed for components of the NF-κB pathway by Western blotting and for
expression of the NF-κB target genes BCL2, CMYC, FAS, PTEN and TNF-α by RT-PCR.
Results: MAP3K7 is deleted in approximately 10% and point-mutated in approximately 1% of children with T-ALL. In 32
of 33 leukemias the deletion of MAP3K7 also included the adjacent CASP8AP2 gene. MAP3K7 deletions were associated
with the occurrence of SIL-TAL1 fusions and a mature immunophenotype, but not with response to treatment and
outcome. Depletion of MAP3K7 expression in T-ALL cell lines by shRNAs slowed down proliferation and induced
apoptosis, but neither changed protein levels of components of NF-κB signaling nor NF-κB target gene expression
after stimulation with TNF-α.
Conclusions: This study revealed that the recurrent deletion of MAP3K7/CASP8AP2 is associated with SIL-TAL1 fusions
and a mature immunophenotype, but not with response to treatment and risk of relapse. Homozygous deletions of
MAP3K7 were not observed, and efficient depletion of MAP3K7 interfered with viability of T-ALL cells, indicating that a
residual expression of MAP3K7 is indispensable for T-lymphoblasts.
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Background
T-cell acute lymphoblastic leukemia (T-ALL) is an
aggressive malignancy of thymocyte progenitors and
constitutes 10–15% of pediatric ALL [1]. With current
treatment protocols, approximately 80% of children
suffering from T-ALL are cured [2, 3]. In a series of 73
primary T-ALL patient samples, Remke et al. (2009)
identified recurrent deletions of 6q14.1–14.3 and 6q15–16.1
that were associated with an unfavorable response to treat-
ment [4]. Of the 16 genes localized in these regions, the
mRNA expression of CASP8AP2 has been shown to be
most strongly affected by the deletion and CASP8AP2 has
been suggested to be a tumor suppressor [4]. Similar 6q15
deletions were found in several cohorts of childhood ALL
and T-cell lymphoblastic lymphomas (T-LBL) [5–10] as well
as in other hematological malignancies [11–14] and in solid
tumors like breast, gastric and prostate cancer [15–18]
(Fig. 1). By whole exome sequencing of T-ALL samples, we
had found recurrent (2/13) mutations in the MAP3K7 gene
which is included within the commonly deleted region
6q15–16.1 [19].
MAP3K7 codes for a mitogen-activated protein kinase
that has alternatively been termed TAK1 (transforming
growth factor beta activated kinase 1) [20]. It is involved
in various inflammatory and immune signaling pathways
like T-cell receptor, Toll-like receptor and TNF-α signal-
ing [21]. Several stimuli lead to association with
TAK1-binding proteins (TAB1–3) [22] followed by an
activation of other mitogen-activated protein kinases
(ERK, JNK, p38) and the transcription factor NF-κB
[23]. Consistently, MAP3K7 knockout in mice resulted
in NF-κB inactivation in T-cells [24] and led to the
development of myelomonocytic leukemia [25]. However,
its distinct biological functions and relevance for different
tumor entities appear to be cell type-specific and remain
controversial [26]. For instance, in prostate cancer
MAP3K7 deletion is associated with an advanced tumor
stage, lymph node metastasis and an early biochemical
recurrence [16, 27], and suppression of MAP3K7 has been
shown to promote tumorigenesis [28]. In contrast,
inhibition of MAP3K7 in breast cancer cells reduced
tumor growth and impaired metastasis [29–31]. In an
AML xenograft model, inhibition of MAP3K7 attenuated
leukemia development [32].
In order to investigate the clinical relevance of
deletions of MAP3K7 in pediatric T-ALL, we analyzed a
cohort of 327 primary T-ALL patient samples for
MAP3K7 deletions and correlated MAP3K7 status with
clinical features. The functional relevance of reduced
MAP3K7 expression in T-ALL cell lines was investigated
by analyzing the effects of shRNA-mediated MAP3K7
depletion on cell proliferation, apoptosis and NF-κB
activation.
Methods
Patients
Patients were treated according to ALL-BFM 2000 [3] or
AIEOP-BFM ALL 2009 protocols. These trials were
registered at www.clinicaltrials.gov (#NCT00430118 and
#NCT01117441). The institutional review boards of
Hannover Medical School (Nr. 2522, November 9th,
2000 and December 22nd, 2008) and University of
Schleswig-Holstein (A 177/09, March 12th, 2010)
approved the trials. Informed consent was obtained in
accordance with the declaration of Helsinki. For further
Fig. 1 Regions of minimal deletion (RMD) on chr6q in pediatric acute lymphoblastic leukemia (ALL) and/or T-cell lymphoblastic lymphoma (T-LBL) as
identified in published studies since 2004. The RMD results were derived from array comparative genomic hybridization (CGH)1, loss of heterozygosity
analysis (LOH)2, single nucleotide polymorphism array analysis (SNP array)3 and fluorescence in situ hybridization (FISH)4. Originally described
nucleotide positions of the proximal and distal boundaries of each RMD were adjusted to the current reference genome GRCh38/hg38 (released in
12/2013). Relative positions of previously suggested potential tumor suppressor genes (EPHA7, GRIK2) and CASP8AP2/MAP3K7 are shown by dashed
lines. A RMD derived from studies of pediatric B- and/or T-ALL samples. B RMD derived from studies in T-LBL
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details refer to the Additional file 1: Supplemental
Methods.
MLPA
Multiplex ligation-dependent probe amplification
(MLPA) was performed using the MRC Holland
(Amsterdam, The Netherlands) SALSA MLPA probe
mix P383-A1 TALL with three additional probes for the
MAP3K7 gene according to the manufacturer’s instruc-
tions. The MAP3K7 probe sequences were:
Exon 1: 5´ GGGTTCCCTAAGGGTTGGACATGT
CTACAGCCTCTGCCGCCTCCTCCTCCTCCT
CGTCTTC/ GGCCGGTGAGATGATCGAAGCCCC
TTCCCAGGTCCTCAACTCTAGATTGGATCT
TGCTGGCAC 3´
Exon 5: 5´ GGGTTCCCTAAGGGTTGGACCACG
CAATGAGTTGGTGTTTACAGTG/ TTCCCAAGG
AGTGGCTTATCTTCACAGCATGCAACCCAA
AGCGTCTAGATTGGATCTTGCTGGCAC 3´
Exon 7: 5´ GGGTTCCCTAAGGGTTGGACGTCT
TCAGCTGGGGTATTATTCTTTGGGAAGTGA
TAACGCG/ TCGGAAACCCTTTGATGAGATTGG
TGGCCCAGCTTCTAGATTGGATCTTGCTGGCAC 3´
Polymerase chain reaction (PCR) products were
separated by capillary electrophoresis on an ABI-3130XL
device. The size standard was GeneScan 500–250 (both
Applied Biosystems).
Cell culture
HEK293T cells were cultured in DMEM medium and
CCRF-CEM, MOLT-4 and Jurkat cells in RPMI 1640
medium (both Gibco). Media were supplemented with 10%
fetal bovine serum and 100 μg/mL penicillin-streptomycin
(Biochrom). All cell lines were cultured at 37 °C and
5% CO2.
AAV vector production
AAV vectors were produced as described previously [33, 34].
Briefly, HEK293T cells were triple-transfected with equal
amounts of an AAV helper plasmid (encoding AAV rep and
cap genes), an AAV vector plasmid encoding the
anti-MAP3K7 shRNA or a non-silencing shRNA and an
adenoviral helper construct. The cap gene AAVrh10A2
was used for the CCRF-CEM cell line and AAV9A2 for
the Jurkat and MOLT-4 cell lines. These are synthetic
AAV cap genes that were created through insertion of
short re-targeting peptides into wild-type AAVrh10 or
AAV9, as recently described [35]. Sense strand nucleotide
sequences for the three anti-MAP3K7 shRNAs were
(positions according to hg38):
shRNA 1 5’ GTGTGTCTTGTGATGGAATA 3′, chr
6:90,561,667–90,561,622
shRNA 2 5’ GCAAGTTCCTGCCACAAATGA 3′, chr
6:90,548,099–90,548,119
shRNA 3 5’ GGACATTGCTTCTACAAATAC 3′, chr
6:90,548,147–90,548,167.
Sense strand nucleotide sequence of non-silencing
control shRNA:
shRNA ns 5’ GTAACGACGCGACGACGTAA 3’
See Additional file 1: Supplemental Methods for
further details on shRNA design and cloning, as well as
on AAV vector production.
Transduction of T-ALL cell lines
T-ALL cells were seeded at a density of 40 cells/μl in
12-well plates and transduced with the shRNA-encoding
AAV vectors at a multiplicity of infection (MOI, i.e.,
vector genomes per cell) between 1*104 to 5*105. Cells
were incubated for 72 h, spun down and resuspended in
fresh medium. For further experiments, cells were either
re-seeded at a density of 40 cells/μl for proliferation ana-
lysis or fixed by adding paraformaldehyde (PFA) to a
final concentration of 4% in phosphate-buffered saline
(PBS, Sigma) and incubating for 30 min at room
temperature. After washing with PBS, transduction rates
were measured by detection of the green fluorescent
protein (GFP) reporter that is co-encoded by all AAV/
shRNA vectors by means of flow cytometry (Cytomics
FC500 MPL analyzer, Beckman Coulter).
Annexin V cell death assay
Six days after transduction, T-ALL cells were counted
and pelleted for staining with an Annexin
V-R-Phycoerythrin (PE) conjugate (BD Biosciences).
Cells were washed twice in Annexin V binding buffer
and then incubated with Annexin V-PE for 15 min at
room temperature. Next, they were fixed with 4% PFA/
PBS, washed once with PBS, and analyzed by flow
cytometry. See Additional file 1: Figure S3 for FACS dot
plots and Additional file 1: Supplemental Methods for
further description.
Quantitative real-time-PCR (qRT-PCR)
Six days after transduction, total RNA was extracted by
using the RNeasy Mini kit (Qiagen) in accordance with
the manufacturer’s instructions. cDNA was synthesized
by using oligo(dT) primers and RevertAid H Minus
M-MuLV Reverse Transcriptase (Thermo Scientific)
according to the manufacturer’s instructions. All quanti-
tative RT-PCR reactions were performed in triplicates by
an ABI StepOnePlus thermocycler (Applied Biosystems)
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with SYBR Green PCR Master Mix (Thermo Scientific).
Primer sequences are listed in Additional file 1: Table S1.
Western blotting
To obtain whole cell lysates, cells were extracted six days
after transduction by use of Mammalian Protein Extraction
Reagent (M-PER, Thermo Fisher Scientific) and subjected
to at least three freeze-thaw cycles (− 80 °C/room
temperature). Samples were run on a sodium-dodecyl
sulfate/ 10% polyacrylamide gel and blotted onto a Westran
S polyvinylidene difluoride membrane (GE Health Care).
After blocking for 24 h in a 5% milk solution, proteins of
interest were detected by incubation for 24 h with anti-
bodies against MAP3K7, NF-κB p100/p52, NF-κB p105/
p50, IκB (all Cell Signaling) used at a 1:1000 dilution in 5%
milk/TBS-T (Tris-buffered saline with 0.5% Tween-20) or
5% BSA (bovine serum albumin)/TBS-T for phospho
NF-κB p65 Ser536 (Cell Signaling). Incubation for 1 h with
a peroxidase-conjugated anti-mouse or anti-rabbit antibody
(both Sigma) was followed by signal detection with Western
Lightning Plus-ECL detection reagent (PerkinElmer) using
the Fusion FX detection system (Vilber Lourmat). ImageJ
(1.48v) was used for quantification of results.
Statistical analysis and graph preparation
Event-free survival (EFS) was defined as the time from
diagnosis to the date of last follow-up in complete
remission or first event. Events were non-response
(defined as not achieving a complete remission after the
first HR-block in ALL-BFM 2000 and after the third
HR-block in AIEOP-BFM ALL 2009), relapse, secondary
neoplasm, or death from any cause. Failure to achieve
remission due to early death or non-response was con-
sidered as event at time zero. Survival was defined as the
time of diagnosis to death from any cause or last
follow-up. The Kaplan-Meier method was used to esti-
mate survival rates, and differences were compared with
the two-sided log rank test. Cox’s proportional hazards
model was used for uni- and multivariate analyses.
Cumulative incidence (CI) functions for competing
events were constructed by the method of Kalbfleisch
and Prentice, and were compared with the Gray’s test
[36]. Results are presented as estimated probability of
5-year EFS (pEFS) and estimated cumulative incidence
of relapse (pCIR) with standard error (± SE). Differences
in the distribution of individual parameters among
patient subsets were analyzed using Fisher’s exact test
for categorized variables and the Mann-Whitney-U test
for continuous variables. Logistical regression was used
to analyze the effect of mutations on response variables
(prednisone response, MRD). All statistical analyses were
conducted using the SAS program (SAS-PC, v. 9.1, SAS
Institute Inc.).
Experimental results were analyzed by Student’s t-tests
as well as one-way and two-way ANOVA. If not stated
otherwise in the figure legends, data are presented as
average ± SE. Graphs and tables were prepared by using
GraphPad Prism6, Microsoft Office 2010 (Excel, Power-
Point) and ImageJ 1.48v. Coffalyser software was used
for MLPA analyses (available at http://www.mlpa.com).
Results
Deletions of MAP3K7 are associated with SIL-TAL1 fusions
and with a mature T-ALL immunophenotype
We performed MLPA on 327 primary T-ALL patient
samples to detect deletions of 6q15 using probes di-
rected against MAP3K7 and CASP8AP2. All patients
had been treated in the ALL-BFM 2000 or in the
AIEOP-BFM ALL 2009 studies and clinical data were
available (Table 1). All deletions of 6q15 were heterozy-
gous. Thirty-two of 33 samples with a MAP3K7 deletion
also showed a loss of the adjacent CASP8AP2 gene. We
assume that all three genes located between MAP3K7
and CASP8AP2 (GJA10, BACH2, MIR4464) and a vari-
able number of adjacent genes are co-deleted in these
leukemias. Only in one sample a MAP3K7 deletion with-
out a CASP8AP2 deletion was detected. These results
support earlier results [4–9] showing that 6q15 deletions
usually affect several genes. Analysis of clinical data of
all 327 pediatric T-ALL patients who had been uniformly
treated with ALL-BFM protocols revealed that the
MAP3K7/CASP8AP2 deletion is significantly associated
with a mature T-ALL immunophenotype (p = 0.0005;
Table 1), but not with any other clinical feature. Specific-
ally, response to treatment as measured by prednisone
response on day 8 and MRD assessment on days 33 and
78 after start of induction treatment did not differ between
patients with or without a MAP3K7 deletion (Table 1).
There was no association ofMAP3K7/CASP8AP2 deletions
with the cumulative incidence of relapse or overall survival
(Fig. 2a). MAP3K7/CASP8AP2 deletions were significantly
more frequently observed in SIL-TAL1 positive than in
SIL-TAL1 negative T-ALLs (p = 0.005). No other genetic
feature including NOTCH1 and PTEN mutations were
associated with MAP3K7 deletion. There was a trend for
SIL-TAL1 positive T-ALL patients harboring a MAP3K7/
CASP8AP2 deletion towards a higher risk of relapse com-
pared to patients with SIL-TAL1 fusion, but without
MAP3K7/CASP8AP2 deletion (p(Gray) = 0.13; Fig. 2b).
Targeted sequencing identified a monoallelic point muta-
tion inMAP3K7 in less than 1% (1 of 147) of a subgroup of
the T-ALL patients [37].
T-ALL cell lines can be efficiently transduced by adeno-
associated viral vectors
To analyze the biological effects of a reducedMAP3K7 ex-
pression, we chose three T-ALL cell lines (CCRF-CEM,
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Jurkat, MOLT-4) that do not carry a MAP3K7 deletion as
assessed by MLPA. MAP3K7 mRNA expression levels were
estimated by quantitative RT-PCR to be similar in all three
cell lines and comparable to those in HEK293 cells
(Additional file 1: Figure S1 A). We aimed at phenocopying
a MAP3K7 deletion by shRNA-mediated depletion. Because
T-ALL cell lines are resistant to common methods of
chemical transfection [38], we used an adeno-associated
viral (AAV) vector-mediated transduction system to effi-
ciently deliver shRNA to our cell lines. Flow cytometry ana-
lysis demonstrated transduction efficiencies mostly above
80% for the cell lines CCRF-CEM and Jurkat (Additional file
1: Figure S1 B). All subsequent experiments with these cell
lines were performed after a transduction efficiency of at
Table 1 Correlation of MAP3K7/CASP8AP2 deletions with clinical features in primary T-ALL patients
Characteristic MAP3K7/CASP8AP2 wildtype (%) MAP3K7/CASP8AP2 deletion (%)
All 294 (100) 33 (100)
Sex Male 213 (72.4) 27 (81.8) p = 0.30
Female 81 (27.6) 6 (18.2)
Age < 10 152 (51.7) 15 (45.5) p = 0.58
≥10 142 (48.3) 18 (54.5)
WBC at diagnosis < 10,000 26 (8.8) 2 (6.1) p = 0.93
10,000–50,000 69 (23.5) 7 (21.2)
50,000–100,000 55 (18.7) 7 (21.2)
≥100,000 144 (49.0) 17 (51.5)
Mediastinal mass Yes 155 (54.2) 16 (48.5) p = 0.58
No 131 (45.8) 17 (51.5)
T-cell immunophenotypea Early (Pro-/Pre-) T-ALL 89 (30.3) 7 (21.2) p = 0.0005
Cortical T-ALL 177 (60.2) 16 (48.5)
Mature T-ALL 24 (8.2) 10 (30.3)
Prednisone response PGR 173 (58.8) 17 (51.5) p = 0.35
PPR 113 (38.4) 16 (48.5)
MRD on day 33 N/A 49 (16.7) 2 (6.1) p = 0.18
Negative 54 (18.4) 4 (12.1)
10−4 76 (25.9) 7 (21.2)
≥10−3 115 (39.1) 20 (60.6)
MRD on day 78 N/A 42 (14.3) 2 (6.1) p = 1.00
< 10−3 221 (75.2) 27 (81.8)
≥10−3 31 (10.5) 4 (12.1)
Risk Group 2000b SR 41 (13.9) 3 (9.1) p = 0.69
MR 127 (43.2) 14 (42.4)
HR 126 (42.9) 16 (48.5)
Genetics: SIL-TAL1 fusion Yes 39 (13.2) 12 (36.4) p = 0.002
No 255 (86.7) 21 (63.6)
WBCWhite blood cell count, PGR/PPR Prednisone good/poor response, MRD Minimal residual disease, SR/MR/HR Standard/Medium/High risk. aEarly = Pro (cyCD3+, CD7+) and
Pre (cyCD3+, CD2+ and/or CD5+ and/or CD8+); cortical (CD1a+); mature (CD1a−, sCD3+). cyCD3+: cytoplasmic CD3+; sCD3+: surface CD3+. bThe ALL-BFM 2000 overall risk
classification defines three groups: SR - prednisone good response on day 8 (< 1000/μL leukemic blasts in peripheral blood) and complete cytomorphologic remission on day
33 and negative MRD on day 33 and day 78; MR - prednisone good response on day 8 and complete cytomorphologic remission on day 33 and MRD positive on day 33
and/or day 78, but < 10−3 on day 78; HR – prednisone poor response on day 8 or no complete cytomorphologic remission on day 33 or MRD on day 78 ≥ 10− 3 [3]
If numbers for clinical data sum up to less than 327, this feature was not available for all patients
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least 80% had been confirmed. However, transduction of
MOLT-4 cells was less efficient and depended on the type of
shRNA, so the threshold for further analysis in this cell line
was set to a transduction efficiency of at least 60%. Deple-
tion efficiency as assessed by quantitative RT-PCR and
Western blotting was uniform, with both MAP3K7 mRNA
and MAP3K7 protein being in the range of 25% of that after
treatment with non-silencing shRNA (Additional file 1:
Figure S1C-D).
MAP3K7 knockdown slows down proliferation in T-ALL
cell lines
Treatment with anti-MAP3K7 shRNA significantly slowed
down proliferation in all three of the T-ALL cell lines ana-
lyzed (Fig. 3a). Five days after transduction, all three
shRNAs resulted in a significant reduction of cell numbers
compared to the non-silencing control (two-way ANOVA
for treatment vs non-silencing control: p(CCRF-CEM) =
0.0044, p(Jurkat) = 0.0057, p(MOLT-4) = < 0.0001). Treat-
ment with shRNA 1 in Jurkat and MOLT-4 cells completely
abrogated cell proliferation and/or led to a loss of cells.
MAP3K7 depletion induces apoptosis in T-ALL cell lines
In order to assess if decreasing cell numbers after deple-
tion of MAP3K7 were due to a higher rate of apoptosis,
we performed an Annexin V assay six days after trans-
duction. Treatment with anti-MAP3K7 shRNA resulted
in an increase in the proportion of Annexin V positive
cells in all three cell lines of up to 8-fold (Fig. 3b). The
extent of this effect depended on the cell type and the
type of shRNA used. In all three cell lines, shRNA 2 had
no or only a marginal effect on the proportion of
Annexin V positive cells, possibly reflecting the relative
low transduction efficiency for the corresponding
shRNA construct. The strongest reduction of cell num-
bers was observed with the shRNA that most strongly
induced apoptosis, suggesting that depletion of MAP3K7
impairs cell density by increasing the rate of apoptosis.
However, the potential to induce apoptosis did not fully
explain the effect on cell numbers, indicating that
further mechanisms influence proliferation.
Effects of MAP3K7 depletion are not mediated by NF-κB
inactivation
MAP3K7 deficiency has been shown to inhibit NF-κB
activation in different cell types [29, 32, 39]. To study
the relevance of this interaction in T-ALL cells, we stimu-
lated cell lines with TNF-α six days after transduction with
shRNAs against MAP3K7 and analyzed protein lysates by
Western blotting for components of the NF-κB pathway
a
b
Fig. 2 Deletion of MAP3K7/CASP8AP2 does not affect outcome of pediatric T-ALL patients. Cumulative incidence of relapse (pCIR) and probability
of event-free survival (pEFS) for T-ALL patients enrolled in ALL-BFM 2000 and ALL-BFM 2009 with MAP3K7/CASP8AP2 wild type (blue) or MAP3K7/
CASP8AP2 deletion (red). Results are presented as estimated probability of 5-year EFS (pEFS) and estimated cumulative incidence of relapse (pCIR)
with standard error (± SE). a T-ALL patients with or without MAP3K7/CASP8AP2 deletion (n = 327). MAP3K7/CASP8AP2 deletion neither affects the
pEFS (p(Log-Rank) = 0.4) nor pCIR (p(Gray) = 0.98). b T-ALL patients with SIL-TAL1 fusion (n = 52) who do or do not carry an additional MAP3K7/
CASP8AP2 deletion. SIL-TAL1 positive patients harboring a deletion of MAP3K7/CASP8AP2 show a trend towards a higher pCIR (p(Gray) = 0.13)
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(Fig. 4). Stimulation with TNF-α led to rapid and transient
degradation of IκB and accumulation of phospho-NF-κB
p65 (Ser536) in both untreated control cells and ns
shRNA-treated cells, while other NF-κB proteins (p100,
p105, p50) remained largely unaffected (Fig. 4a). Depletion
ofMAP3K7 mediated by shRNAs 1 and 3 neither changed
IκB levels in unstimulated cells nor did it prevent the
degradation of IκB after stimulation with TNF-α. shRNA
2 partially impaired degradation of IκB (Fig. 4b).
Next, we asked if MAP3K7 depletion influences
expression levels of NF-κB target genes. We extracted
total RNA from T-ALL cells after MAP3K7 depletion
and analyzed mRNA expression levels of five NF-κB
target genes (BCL2 [40], CMYC [41], PTEN [42], TNF-α
[43, 44], FAS [45, 46]) by quantitative RT-PCR. Expres-
sion of none of these genes was consistently changed by
more than two-fold in any of the cell lines (Fig. 4c), indi-
cating that the effect of NF-κB on gene expression does
not depend on MAP3K7. We conclude that in T-ALL
cell lines, MAP3K7 is not required for the degradation
of IκB and subsequent activation of NF-κB after stimula-
tion with TNF-α.
a b
Fig. 3 MAP3K7 depletion decreases proliferation and induces apoptosis in T-ALL cell lines. T-ALL cell lines were transduced with AAV vectors
coding for three different shRNAs (1, 2, 3) and one non-silencing shRNA (ns). Transduction efficiency was controlled by flow cytometry after 72 h
of incubation. a MAP3K7 depletion reduces proliferation of T-ALL cells. After exchanging the culture medium three days after transduction, cells
were seeded at a density of 40 cells/μl. Every 24 h, an aliquot was stained by Trypan blue and vital cells were counted in a hemocytometer
(Neubauer improved, Assistent). Relative proliferation was defined as the ratio of cell numbers on the day of interest over the starting cell
number. Means of relative proliferation and standard deviations are given in the graph. Significance of differences in proliferation rates were
calculated by two-way ANOVA and Student’s t-test compared to shRNA ns on day 5 of counting (* = p < 0.05, ** = p < 0.01, *** = p < 0.001, ****
p < 0.0001, n(CCRF-CEM, MOLT-4) = 3, n(Jurkat) = 5). b MAP3K7 depletion sensitizes T-ALL cells for apoptosis. Six days after transduction, apoptotic
cells were stained with PE-conjugated Annexin V and measured by flow cytometry. Dot plot gates for untreated control were set to have less
than 1% apoptotic cells. Gates of transduced cells were adjusted accordingly. The percentage of Annexin V-positive cells was compared between
treatment with non-silencing shRNA (ns) and shRNAs 1, 2 and 3 directed against MAP3K7. Results are presented as means and standard deviations of
PE-positive cells in percent. Significance was calculated by unpaired t-test compared to non-silencing shRNA (* = p < 0.05, ** = p < 0.01, *** = p < 0.001,
**** p < 0.0001, n(CCRF-CEM, Jurkat) = 3, n(MOLT-4) = 6)
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Discussion
We confirmed in a large cohort that heterozygous dele-
tions of 6p15, including the MAP3K7 locus, are a fre-
quent event in T-ALL. In contrast, point mutations in
MAP3K7 were observed in less than 1% of primary
T-ALLs [37]. MAP3K7 deletions were associated with
the presence of SIL-TAL1 fusions and a mature immuno-
phenotype. Although leukemias with TAL1 overexpres-
sion were described to reflect the late cortical stage of
thymocyte differentiation [47], SIL-TAL1 fusions were
not associated with a certain immunophenotype in our
and published cohorts [48]. We therefore hypothesize
that the deletion of MAP3K7/CASP8AP2 or another
gene on 6q15 may directly influence the expression of
T-cell surface markers. Alternatively, T-ALL cells that
resemble a mature thymocyte may be less dependent on
high expression levels of MAP3K7 and thus less vulner-
able to deletions of 6q15 in comparison to cortical or
even less mature T-ALLs. No other clinical features were
correlated with deletions of MAP3K7. Importantly,
MAP3K7 deletions neither predicted treatment response
nor the risk of relapse. Previous studies identified several
mostly overlapping regions on chr 6q that are recur-
rently deleted in pediatric T-ALL and T-lymphoblastic
lymphoma (Fig. 1, [7]). The centromeric region is local-
ized on 6q14 and 6q15 and involves, among others,
MAP3K7 and CASP8AP2. In a smaller cohort of
patients, this deletion has been associated with a poor
response to induction treatment [4]. However, we
neither found an association of MAP3K7/CASP8AP2
deletions with an unfavorable treatment response nor
with the cumulative incidence of relapse. Obviously, de-
letions of MAP3K7 are not a useful prognostic marker
in the context of ALL-BFM 2000 and AIEOP-BFM ALL
2009 protocols. Future studies investigating the prognostic
relevance of deletions on chr6q in T-ALL will ideally use
high resolution mapping of copy number alterations in a
large cohort of patients. Our work extends earlier findings
that suggest that the effect of MAP3K7 deletions on
the prognosis of malignancies is highly dependent on
the cell of origin: MAP3K7 deletions are associated
with advanced high-risk disease in prostate cancer
[16, 27], but with a good prognosis in esophageal
squamous cell carcinoma [49]. The effect on the
a
b
c
Fig. 4 MAP3K7 depletion does not inhibit NF-κB activation after stimulation of T-ALL cell lines with TNF-α. Six days after transduction with anti-MAP3K7
shRNA, T-ALL cell lines were stimulated with TNF-α (10 ng/μl) for 30 min and whole cell lysates were analyzed by Western blotting. a Stimulation of non-
transduced T-ALL cells results in degradation of IκB. b MAP3K7 depletion does not prevent degradation of IκB after stimulation with TNF-α. c Treatment
with anti-MAP3K7 shRNA did not consistently change expression patterns of NF-κB target genes in T-ALL cell lines. Six days after transduction with anti-
MAP3K7 shRNA, total RNA was extracted, cDNA was synthesized and MAP3K7 mRNA expression quantified by qRT-PCR. HPRT1 was used as internal control.
Mean values and SE of expression levels are given (n= 3). CCRF-CEM carries a PTEN deletion and does not express PTEN [62]
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prognosis of pediatric T-ALL seems to be very limited
with current treatment protocols.
Transduction of T-ALL cell lines by AAV was efficient
and resulted in transgene delivery efficiencies exceeding
those typically reached by chemical transfection [38].
The simulation of MAP3K7 deletion by AAV-mediated
shRNA depletion resulted in slower proliferation and
increased apoptosis in all cell lines analyzed. The specifi-
city of the effect of MAP3K7 depletion was confirmed
with three different shRNA constructs in three different
cell lines. Of note, the restraints in insert size in our
AAV vectors did not allow rescue experiments reversing
the effects of the depletion by ectopic expression of
MAP3K7, so we cannot fully exclude off target effects.
It has previously been shown that MAP3K7 is indis-
pensable for thymocyte and T-cell development [24, 50].
Similar observations in different cancer models have pri-
marily been attributed to an inactivation of the NF-κB
pathway upon MAP3K7 inhibition [25, 29]. For instance,
chemical inhibition of MAP3K7 completely abolished
NF-κB activation in AML cells, leading to cell death by
apoptosis and decreased expression of IL8 [32]. The
expression of a constitutively activated NF-κB p65
subunit only partially reduced these effects, indicating
that MAP3K7 signaling was not restricted to NF-κB
activation [32]. Similarly, our results neither showed an
effect on IκB levels nor on NF-κB target gene expression
as a response to MAP3K7 depletion. We conclude that
the biologic effects of MAP3K7 depletion were inde-
pendent of the NF-κB pathway. Several genes recurrently
mutated in T-ALL influence the MAP3K7/NF-κB signal-
ing pathway. Most prominently, NOTCH1 directly inter-
acts with NF-κB proteins and the IKK complex, leading
to their activation [51]. Both MOLT-4 and CCRF-CEM
cell lines carry NOTCH1 mutations [52], and MAP3K7
might not be required additionally to activate NF-κB
and the IKK complex. Furthermore, the function of
MAP3K7 may not only depend on mutations in genes
that can activate or inactivate NF-κB, but also on the cell
type and the maturation stage. Specifically, MAP3K7 has
a critical role for NF-κB activation in naïve T-cells, but
is dispensable in effector T-cells [53]. This observation
may also explain why deletions of MAP3K7 are found
more frequently among leukemias with a more mature
immunophenotype: Possibly “mature” lymphoblasts - in
contrast to lymphoblasts resembling less mature precursors
- do not depend on MAP3K7 for the activation of the
NF-κB pathway, which has been shown to be required for
leukemogenesis in several models [51, 54–56]. As we did
not find a direct effect ofMAP3K7 depletion on the activity
of NF-κB, we suggest that MAP3K7 has an effect on cell
proliferation that is independent from NF-κB.
Notably, our data do not formally exclude that the low
MAP3K7 protein levels remaining after AAV-mediated
depletion have different biological effects than the higher
MAP3K7 protein levels remaining in cells carrying
heterozygous deletions. We never observed homozygous
deletions of MAP3K7 or the combination of a heterozy-
gous deletion and a mutational inactivation of the
remaining allele, indicating that some residual MAP3K7
activity is required for survival and proliferation of
T-ALL cells. Although our results do not argue for a
biological effect of monoallelic deletions of MAP3K7 in
T-ALL, the fact that T-ALL cells require residual expres-
sion of MAP3K7 may imply the potential of MAP3K7 as
a new treatment target: If MAP3K7 is not a tumor
suppressor but co-deleted with another, yet to be identi-
fied tumor suppressor on 6q15, it may behave as a
“CYCLOPS” gene [57]. Accordingly, MAP3K7 deletion
may render leukemia cells highly vulnerable to inactiva-
tion of the remaining MAP3K7 allele. Possible candidate
drugs that may be able to exploit this potential Achilles’
heel are chemical MAP3K7 inhibitors like (5Z)-7-Oxozeae-
nol, LYTAK1, AZ-TAK1 and NG52, which showed
anti-tumor effects in various in vivo and in vitro cancer
models but do not appear suitable for the use in a clinical
setting due to low selectivity [58]. However, the multikinase
inhibitor sorafenib [59], which has already been proven to
be clinically effective in the treatment of various malignan-
cies, inhibits MAP3K7 and may specifically target leuke-
mias with low expression of MAP3K7 [60, 61].
Conclusions
Our results show that heterozygous MAP3K7 deletions
are recurrently found in T-ALL patients, but do not
affect patients’ outcome in the context of ALL-BFM
treatment protocols. On a cellular level, MAP3K7 is es-
sential for rapid proliferation and inhibition of apoptosis.
In contrast to previous observations, we did not find in-
activation of NF-κB to be the mechanism underlying the
biological effects of MAP3K7 inactivation in T-ALL cell
lines. The complete absence of homozygous MAP3K7
deletions and the proliferation arrest after efficient
depletion indicate that MAP3K7 may be indispensable
for T-ALL cells and thus a potential target for treatment.
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